Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201

Fibroblast growth factor receptor 3 (FGFR3) alterations are oncogenic drivers of urothelial carcinoma (UC). Pemigatinib is a selective, oral inhibitor of FGFR1-3 with antitumor activity. We report the efficacy and safety of pemigatinib in the open-label, single-arm, phase II study of previously trea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2024-02, Vol.35 (2), p.200-210
Hauptverfasser:	Necchi, A., Pouessel, D., Leibowitz, R., Gupta, S., Fléchon, A., García-Donas, J., Bilen, M.A., Debruyne, P.R., Milowsky, M.I., Friedlander, T., Maio, M., Gilmartin, A., Li, X., Veronese, M.L., Loriot, Y.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Antineoplastic Agents - adverse effects Carcinoma, Transitional Cell - drug therapy FGFR Genomics Humans metastatic urothelial carcinoma Morpholines pemigatinib precision medicine Pyrimidines Pyrroles resistance targeted therapy Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!